Phathom Pharmaceuticals Inc (PHAT)

$8.54 -0.52 (-5.74%)
Market Cap 640.89M
Revenue (ttm) 55.25M
Net Income (ttm) -334.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -605.12%
Debt to Equity Ratio -0.60
Volume 882,300
Avg Vol 3,157,814
Day's Range N/A - N/A
Shares Out 69.81M
Stochastic %K 55%
Beta 0.45
Analysts Strong Sell
Price Target $19.00

Company Profile

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heart...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 742 8466
Address:
100 Campus Drive, Suite 102, Florham Park, United States
longshot45
longshot45 Jul. 15 at 7:39 PM
$PHAT Silly algos playing their games… thanks for the extra shares at 8.30.
1 · Reply
Morrito23
Morrito23 Jul. 15 at 7:26 PM
$PHAT oh how I wish I had more cash for this right about now
0 · Reply
Joe_90_
Joe_90_ Jul. 15 at 4:41 PM
$PHAT added
1 · Reply
Hendo111
Hendo111 Jul. 15 at 4:09 PM
$PHAT added
0 · Reply
Joe_90_
Joe_90_ Jul. 15 at 3:35 PM
$PHAT folks its just an attempt for shorties to cover
0 · Reply
Hendo111
Hendo111 Jul. 15 at 3:06 PM
$PHAT
0 · Reply
Walleyeslayer
Walleyeslayer Jul. 15 at 2:57 PM
$PHAT down 60 cents on 150K volume. Hold on tight! Gonna get bumpy into the ER
0 · Reply
Withermania
Withermania Jul. 15 at 12:51 PM
$PHAT I like this setup into earnings early august. Big investors want to see numbers much better than Q1. I think they’ll get them. This gets momentum following earnings it wouldn’t shock me to see a buy out now that the patent issue is behind. Accumulating around $9 seems like a no brainer
1 · Reply
RobertPerron428
RobertPerron428 Jul. 15 at 2:39 AM
$PHAT Monitoring clean pullbacks only
0 · Reply
Hendo111
Hendo111 Jul. 14 at 2:34 PM
$PHAT $LCTX $MBIO $CEIN
1 · Reply
Latest News on PHAT
Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism

Jun 25, 2025, 4:54 AM EDT - 20 days ago

Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 23, 2025, 4:15 PM EDT - 22 days ago

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

Jun 23, 2025, 7:59 AM EDT - 22 days ago

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

SAGE

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

Jun 16, 2025, 8:00 AM EDT - 4 weeks ago

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy

Jun 10, 2025, 10:08 AM EDT - 5 weeks ago

Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

Jun 6, 2025, 12:27 PM EDT - 5 weeks ago

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

May 15, 2025, 7:59 AM EDT - 2 months ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript

May 1, 2025, 12:09 PM EDT - 2 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 7:00 AM EDT - 2 months ago

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ITCI

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

Apr 28, 2025, 7:59 AM EDT - 2 months ago

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

Apr 23, 2025, 8:00 AM EDT - 2 months ago

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

Frazier Life Sciences Appoints Aditya Kohli to Partner

Apr 17, 2025, 8:00 AM EDT - 3 months ago

Frazier Life Sciences Appoints Aditya Kohli to Partner

HLVX

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

Apr 16, 2025, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

CDTX

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Phathom Pharmaceuticals Announces Leadership Succession

Apr 1, 2025, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals Announces Leadership Succession

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

Mar 31, 2025, 7:59 AM EDT - 3 months ago

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 12:13 PM EST - 4 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 6, 2025, 8:00 AM EST - 4 months ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Feb 24, 2025, 8:00 AM EST - 5 months ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Jan 29, 2025, 8:00 AM EST - 5 months ago

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Dec 11, 2024, 8:00 AM EST - 7 months ago

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript

Nov 10, 2024, 3:54 AM EST - 8 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Oct 28, 2024, 8:00 AM EDT - 9 months ago

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Oct 27, 2024, 12:00 PM EDT - 9 months ago

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Aug 19, 2024, 8:00 AM EDT - 11 months ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 2:52 PM EDT - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

Jul 18, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

Jun 26, 2024, 6:11 AM EDT - 1 year ago

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript

May 11, 2024, 7:03 PM EDT - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion

Mar 18, 2024, 1:19 AM EDT - 1 year ago

Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 2:11 PM EST - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 7, 2024, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

Feb 29, 2024, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Phathom Pharma Is A Buy Before July PDUFA

Jan 1, 2024, 6:41 AM EST - 1 year ago

Phathom Pharma Is A Buy Before July PDUFA

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

Dec 6, 2023, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

Nov 28, 2023, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates

Nov 9, 2023, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

Nov 1, 2023, 5:00 PM EDT - 1 year ago

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

Oct 30, 2023, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

Following Up On Phathom Pharmaceuticals

Oct 5, 2023, 12:43 PM EDT - 1 year ago

Following Up On Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

Sep 26, 2023, 8:01 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application

Aug 21, 2023, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application

Phathom Pharmaceuticals Reports Second Quarter 2023 Results

Aug 10, 2023, 8:01 AM EDT - 2 years ago

Phathom Pharmaceuticals Reports Second Quarter 2023 Results

Phathom Pharma: Time To Take Profits (Rating Downgrade)

Jul 14, 2023, 4:12 PM EDT - 2 years ago

Phathom Pharma: Time To Take Profits (Rating Downgrade)

longshot45
longshot45 Jul. 15 at 7:39 PM
$PHAT Silly algos playing their games… thanks for the extra shares at 8.30.
1 · Reply
Morrito23
Morrito23 Jul. 15 at 7:26 PM
$PHAT oh how I wish I had more cash for this right about now
0 · Reply
Joe_90_
Joe_90_ Jul. 15 at 4:41 PM
$PHAT added
1 · Reply
Hendo111
Hendo111 Jul. 15 at 4:09 PM
$PHAT added
0 · Reply
Joe_90_
Joe_90_ Jul. 15 at 3:35 PM
$PHAT folks its just an attempt for shorties to cover
0 · Reply
Hendo111
Hendo111 Jul. 15 at 3:06 PM
$PHAT
0 · Reply
Walleyeslayer
Walleyeslayer Jul. 15 at 2:57 PM
$PHAT down 60 cents on 150K volume. Hold on tight! Gonna get bumpy into the ER
0 · Reply
Withermania
Withermania Jul. 15 at 12:51 PM
$PHAT I like this setup into earnings early august. Big investors want to see numbers much better than Q1. I think they’ll get them. This gets momentum following earnings it wouldn’t shock me to see a buy out now that the patent issue is behind. Accumulating around $9 seems like a no brainer
1 · Reply
RobertPerron428
RobertPerron428 Jul. 15 at 2:39 AM
$PHAT Monitoring clean pullbacks only
0 · Reply
Hendo111
Hendo111 Jul. 14 at 2:34 PM
$PHAT $LCTX $MBIO $CEIN
1 · Reply
Hendo111
Hendo111 Jul. 14 at 3:02 AM
$PHAT
0 · Reply
Withermania
Withermania Jul. 11 at 4:24 PM
$PHAT no volume here. Wouldn’t be shocked to see a rebound late in the day. Script count is rapidly growing and expect billings to surprise in Q2 as insurance delays get sorted after a dismal Q1. This is primed to move back into $15ISH in the coming couple months
1 · Reply
RonIsWrong
RonIsWrong Jul. 10 at 10:09 PM
$PHAT lowest short interest in at least a year.
1 · Reply
RunnerSignals
RunnerSignals Jul. 10 at 8:50 PM
comeback kings flex $ACDC $PHAT $PRME $TALO $NAMS bounce off lows, closing the day with a victory dance!
0 · Reply
StardustTrader
StardustTrader Jul. 10 at 8:01 PM
$PHAT what, no end of day selling??
0 · Reply
Walleyeslayer
Walleyeslayer Jul. 10 at 4:57 PM
$PHAT Only a matter of time here!
2 · Reply
Tumble51
Tumble51 Jul. 10 at 2:58 PM
$PHAT you got TED S on the board GOOD FCUKIN LUCK HE BANKRUPTED his LAST VENTURE Nabrivia Pharma ..a ceo there that RUINED the company LOSER TED WAKE THE FCUK UP
2 · Reply
SmittyWJMJ
SmittyWJMJ Jul. 9 at 6:29 PM
$PHAT $AZZ what a great combo. $QQQ $SPY $NVDA
0 · Reply
Jacobi
Jacobi Jul. 9 at 6:13 PM
$AZZ meet your friend, $PHAT
1 · Reply
StardustTrader
StardustTrader Jul. 9 at 4:56 PM
$PHAT P-CAB > PPI. Nuff said
0 · Reply
stocksUP59
stocksUP59 Jul. 9 at 3:19 PM
$PHAT nice momentum
2 · Reply
Hendo111
Hendo111 Jul. 9 at 2:00 PM
$CEIN $LCTX $LAES $AKBA $PHAT 💚
0 · Reply